HSP90AA1 and neoplasm: Remarkably, the Hsp90 inhibitor, AUY-922, can facilitate PD-L1 degradation via lysosomes and boost anti-tumor immunity by augmenting Hsc70 expression, which can serve as a potential drug candidate for combinational immunotherapy.